Name: Restless Legs Syndrome: Check Your Iron Before You Reach for a Drug
Creator: Realised
Published: 2026-06-01

Summary

Restless legs syndrome is a real neurological sensorimotor disorder with a brain-iron substrate, not anxiety, "growing pains," or something in your head — so the single most under-used move is to check ferritin and replete iron toward roughly 75–100 µg/L when it is low, then screen for a removable trigger (a sedating antihistamine, an SSRI/SNRI, alcohol) before adding any chronic drug; if medication is needed, modern guidance favours the alpha-2-delta ligands (gabapentin/pregabalin) over the old first-line dopamine agonists, because the agonists buy short-term relief at the cost of long-term a

Why Strong

Strong Evidence because the load-bearing claims — RLS is a genuine neurological disorder with a brain-iron substrate, low ferritin is a treatable central driver, and dopamine agonists cause augmentation — rest on multiple society guidelines (IRLSSG iron consensus 2018, AASM 2024), the field-standard diagnostic criteria (IRLSSG 2014, mirrored in DSM-5), high heritability with replicated risk genes, and convergent neuropathology/imaging.

NOT Foundational because it carries genuine clinical and commercial judgement and a two-sided controversy (over-treatment vs over-supplementation), not a single undisputed axiom.

NOT Moderate for the headline, because the spine of the entry — diagnosis, brain-iron substrate, augmentation, and the 2024 first-line flip — is guideline- and neuropathology-backed, not a handful of suggestive studies.

The per-sub-area split (read this, not just the headline):
• Diagnostic criteria: Strong — field-standard, DSM-5-mirrored.
• Biological substrate (genetics + low brain iron): Strong — convergent genetics and neuropathology.
• Iron repletion when ferritin low: Strong — IRLSSG consensus with a defined ferritin target.
• Augmentation exists and matters: Strong; precise incidence: Moderate (heterogeneous estimates).
• Secondary causes / culprit drugs: Strong-to-Moderate — well-documented associations, variable individual weight.
• Magnesium: Experimental / insufficient — one underpowered negative RCT plus case reports; flagged explicitly.

Practical takeaway

The order of operations: confirm → check iron → remove a trigger → then, if needed, the right drug.

Step 1 — Confirm it's actually RLS.
• Run the five criteria: an urge to move (usually with uncomfortable sensations), worse at rest, relieved by movement while it continues, worse in the evening/night, and not better explained by a mimic (cramp, neuropathy, akathisia, positional discomfort).
• If it doesn't fit all five, it may not be RLS — and the iron/augmentation logic below may not apply.

Step 2 — Check ferritin (and transferrin saturation) before anything else.
• This is the most under-used lever. Ask for a ferritin level. If it is low (the RLS treatment threshold is around or below 75 µg/L, higher than the anaemia threshold), iron repletion is genuinely effective and addresses the cause.
• Do not self-load iron blind. Iron repletion is a clinician-guided, ferritin-driven decision; the dosing, oral-versus-IV choice, and overload guardrails live in iron_supplementation_repletion_and_overload.
• Caveat to hold: iron helps mainly when ferritin is low. Normal-ferritin RLS often still needs other management — "check your iron first" is not "iron always works."

Step 3 — Hunt for a removable trigger.
• Review (with a clinician, not unilaterally) whether a sedating antihistamine (diphenhydramine), an SSRI/SNRI/TCA, a dopamine-blocking antipsychotic or anti-nausea drug, or lithium is in the picture. Alcohol and caffeine commonly worsen symptoms too.
• If a culprit drug can be substituted (e.g. bupropion does not exacerbate RLS and may suit some depression cases), that can fix the problem at the source. Never stop a prescribed antidepressant on your own — abrupt SSRI cessation is harmful; this is a clinician conversation.
• Treat secondary causes: pregnancy-related RLS usually resolves within days postpartum; ESRD-related RLS needs specialist/renal management.

Step 4 — If medication is warranted, favour the right class.
• Modern guidance favours the alpha-2-delta ligands (gabapentin, gabapentin enacarbil, pregabalin) over dopamine agonists, because the agonists cause augmentation over time.
• The alpha-2-delta ligands are not "natural" or benign — they cause sedation, dizziness, edema, weight gain, and carry misuse/dependence potential. This is a prescribing decision with real trade-offs.

On magnesium and "natural cures":
• Magnesium is low-risk to try, but the evidence is thin (one underpowered negative RCT plus case reports). Frame it as "maybe, low downside," never as a cure. If you want the general magnesium-for-sleep picture, see magnesium_supplementation_sleep.

Evidence detail

Why This Entry Exists

Restless legs syndrome sits at an awkward intersection: it is simultaneously under-recognised (dismissed as anxiety, fidgeting, or "growing pains") and mistreated (handed a dopamine agonist that works for a year and then quietly makes the condition worse). Both failures are avoidable, and both have a clean evidence base behind the fix. The condition has consistent diagnostic criteria, high heritability with replicated risk genes, and convergent neuropathology showing low regional brain iron. That is the part that defeats "it's just in your head."

But the topic is also a magnet for the supplement market, where magnesium in particular gets sold as a cure on the strength of one underpowered negative trial and a handful of case reports. And a large fraction of cases are secondary — driven by pregnancy, kidney failure, iron deficiency itself, or a culprit medication — meaning the right move is often to remove something, not add something.

So this entry is the one-stop for recognising RLS and ordering the levers correctly: confirm it's actually RLS, check iron first, hunt for a removable trigger, and only then reach for a drug — and if you do, reach for the right class. It defers the iron-dosing mechanics to iron_supplementation_repletion_and_overload and the sedative-hypnotic detail to hypnotic_medications_overview.

What bad advice this protects against, in all directions:
• "It's just anxiety / restlessness / growing pains — relax and it'll pass." → False. RLS is a heritable neurological disorder with a brain-iron substrate and field-standard diagnostic criteria; dismissal delays a cheap, effective workup.
• "Take magnesium, it cures restless legs." → Thin evidence. One small RCT (negative, likely underpowered) plus case reports; no society recommends it as standard therapy. Low-risk to try, but sell it as "maybe," not "cure."
• "Get on a dopamine drug, they work great." → They work great short-term, then cause augmentation — an iatrogenic, dose-driven worsening that flipped 2024 first-line guidance toward alpha-2-delta ligands. The short-term win hides a long-term liability.
• "Just supplement iron, it's safe." → Not unconditionally. Iron helps mainly when ferritin is low, and blanket iron without a ferritin/transferrin-saturation check risks overload. Check first; dosing lives in iron_supplementation_repletion_and_overload.
• "Every leg discomfort at night is RLS." → No. The five criteria (including relief by movement and evening predominance) exist precisely to exclude cramps, neuropathy, akathisia, and positional discomfort.

This entry owns recognition + the iron lever + the augmentation trap + secondary causes. It does not re-argue iron dosing/overload (iron_supplementation_repletion_and_overload), sleeping-pill pharmacology (hypnotic_medications_overview), or general sleep fragmentation (sleep_continuity). It states those boundaries and defers.

Evidence

Organised by sub-area, tier signal inline. The headline is Strong, but magnesium specifically is Experimental — read the tiers, not just the thesis.

Recognition — the diagnostic criteria (Strong Evidence).

1. The five essential URGE-type criteria, all required. The 2014 IRLSSG revised consensus criteria require ALL FIVE features: (1) an urge to move the legs, usually accompanied by uncomfortable sensations; (2) onset or worsening at rest or during inactivity; (3) partial or complete relief by movement, for as long as the movement continues; (4) evening or night predominance; and (5) the features are not solely accounted for by another condition or mimic. These exist specifically to separate true RLS from leg cramps, peripheral neuropathy, akathisia, and positional discomfort. (Allen RP et al., "Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated IRLSSG consensus criteria," Sleep Medicine, 2014; mirrored in DSM-5. Strong Evidence — field-standard criteria, no commercial incentive to over- or under-diagnose.)

It's biological, not psychiatric — genetics + neuropathology (Strong Evidence for the substrate).

2. High heritability with replicated risk genes, and low regional brain iron. Twin and family studies put RLS heritability at roughly 54–70%, with replicated GWAS risk variants including MEIS1 and BTBD9 (the latter contributing a substantial share of population risk). Neuropathology and imaging consistently show decreased iron in the substantia nigra and thalamus alongside dopaminergic changes (reduced putaminal D2 receptors, increased substantia-nigra tyrosine hydroxylase), and MEIS1 variants are linked to altered brain iron-handling gene expression. This convergence — genetics plus neuropathology pointing at a brain-iron/dopamine axis — is the evidence that defeats the "it's just anxiety / growing pains" dismissal. (Trenkwalder C & Paulus W and colleagues, "Iron, dopamine, genetics, and hormones in the pathophysiology of restless legs syndrome," Journal of Neurology, 2017; review "RLS: From Pathophysiology to Clinical Diagnosis and Management," Frontiers in Aging Neuroscience, 2017, PMC5454050. Strong Evidence for the existence of a biological substrate; precise mechanism remains an active research area. Academic, no commercial driver.)

The iron lever — the central modifiable driver (Strong Evidence).

3. Check ferritin and replete toward ~75 µg/L; iron corrects a biological abnormality, not a generic deficiency. The IRLSSG iron-treatment consensus rates oral iron (65 mg elemental) as "possibly effective" for RLS when serum ferritin is at or below 75 µg/L, and intravenous ferric carboxymaltose (1000 mg) as "effective" for moderate-to-severe RLS when ferritin is below 300 µg/L, stating it "could be used as first-line treatment in adults." This establishes the ferritin-target-around-75 lever and frames iron repletion as correcting low brain iron rather than topping up a generic supplement. (Allen RP, Picchietti DL, Auerbach M et al., "Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report," Sleep Medicine, 2018. Strong Evidence — international study-group consensus grounded in graded evidence. NOTE: IV-iron researcher among authors with industry ties — the IV-iron line aligns with that interest, but the oral-iron-first, ferritin-threshold framing is conservative and the brain-iron mechanism is independently supported. Dosing/overload detail deferred to iron_supplementation_repletion_and_overload.)

The augmentation trap — why guidance flipped (Strong that it's real; Moderate on the exact rate).

4. The 2024 AASM guideline reversed first-line treatment, away from dopamine agonists. The 2024 American Academy of Sleep Medicine clinical practice guideline (an update of the 2012 parameter, ~28 recommendations) recommends the alpha-2-delta ligands — gabapentin enacarbil, gabapentin, pregabalin — and conditionally recommends against routine use of the dopaminergic agents ropinirole, pramipexole, rotigotine, and levodopa, reversing the prior first-line standard. The stated reason: dopaminergics show strong short-term efficacy but worsen the underlying RLS over time via dopaminergic plasticity (augmentation). (Winkelman JW et al., "Treatment of restless legs syndrome and periodic limb movement disorder: an AASM clinical practice guideline," Journal of Clinical Sleep Medicine, 2024. Strong Evidence — major sleep-medicine society guideline, systematic-review-based. The direction runs AGAINST dopamine-agonist makers' commercial interest, which strengthens credibility.)

5. Augmentation is a recognised, dose-driven iatrogenic worsening — but the pivotal trials were too short to see it. Augmentation presents as earlier daily symptom onset, greater intensity, spread to the arms or trunk, shorter rest-to-onset latency, and a diminishing drug response that prompts dose escalation. Reported incidence varies widely by study design — roughly 7–10% per year of new augmentation, with cumulative community/clinic prevalence around 20–30%, and head-to-head community rates near 24% (ropinirole) versus 11% (pramipexole). Crucially, the pivotal FDA-approval trials ran only about 12 weeks — far too short to detect a complication that emerges over years. (Garcia-Borreguero D and colleagues' augmentation literature; community augmentation-rate data; summarised in "Exploring the causes of augmentation in restless legs syndrome," Frontiers in Neurology, 2023, and the 2024 AASM guideline. Strong Evidence that augmentation is real and clinically important; Moderate on precise incidence — estimates are heterogeneous. Disclosure of this risk runs counter to manufacturer interest, again credibility-strengthening; the 12-week pivotal duration is a classic case of trial length favouring the drug.)

Secondary and reversible causes — remove a trigger before adding a drug (Strong-to-Moderate).

6. Many RLS cases are secondary; pregnancy and ESRD are common, and a culprit-drug list recurs. Pregnancy: roughly 20–22% of pregnant women develop RLS, peaking in the third trimester, with symptoms typically improving rapidly after delivery and prevalence falling toward baseline over the following weeks to months. End-stage renal disease / hemodialysis: prevalence around 25–50%, often worse during dialysis. Common drug triggers and exacerbators: sedating antihistamines (diphenhydramine), most serotonergic antidepressants (SSRIs, SNRIs, TCAs), dopamine-blocking antipsychotics and anti-nausea agents, lithium, and alcohol/caffeine — with bupropion notable as not exacerbating (and useful for depression in RLS patients). Iron deficiency itself is a leading secondary driver, which is why the iron lever comes first. (StatPearls "Restless Legs Syndrome," NCBI Bookshelf NBK430878; ESRD/hemodialysis review, PMC7510539; RLS-and-pregnancy review literature, ~2014. Strong-to-Moderate — well-documented secondary associations and a consistent culprit-drug list; individual causal weight varies. Educational/review sources, no commercial bias. This is the "remove a trigger before adding a drug" lever to foreground.)

Magnesium — the over-sold "natural cure" (Experimental / insufficient evidence).

7. Magnesium for RLS rests on thin evidence; no society recommends it as standard therapy. The only systematic review of magnesium for RLS / periodic limb movement disorder identified just eight studies — one RCT (which did not find a significant effect and was likely underpowered) plus three case series and four case reports — and concluded there is insufficient evidence to determine efficacy. A later small magnesium+B6 RCT reported benefit but is small and not practice-changing. (Marshall NS, Serinel Y et al., "Magnesium supplementation for the treatment of restless legs syndrome and periodic limb movement disorder: a systematic review," Sleep Medicine Reviews, 2019; later small magnesium+B6 RCT, PMC9804944. Experimental / insufficient for magnesium specifically — flag explicitly to counter the supplement market. Independent systematic review; the finding is unfavourable to the supplement industry. Magnesium-for-sleep generally is owned by magnesium_supplementation_sleep.)

Mechanism

Why iron is the central lever. RLS tracks not with blood iron so much as with brain iron. Neuropathology and imaging show reduced iron in the substantia nigra and thalamus, and iron is a cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis. The working model: low regional brain iron destabilises the dopaminergic system, producing the circadian-timed sensorimotor urge. Serum ferritin is an imperfect proxy for brain iron, but it is the practical handle we have — and because ferritin can sit "normal" while brain iron is low, the treatment target (around 75–100 µg/L) is set higher than the threshold used to define ordinary iron-deficiency anaemia. That higher bar is the whole point: you are repleting toward a brain need, not just correcting anaemia.

Why dopamine agonists work then betray. Dopamine agonists acutely relieve symptoms by substituting for the under-stimulated dopaminergic system. But over months to years, chronic agonist exposure appears to drive compensatory plasticity — effectively pushing the system toward a state that needs more drug and produces symptoms earlier in the day, more intensely, and over a wider body area. That is augmentation. The mechanism is why the short-term trial result is misleading: the drug genuinely works at 12 weeks and genuinely worsens the disorder by year two or three. Alpha-2-delta ligands (gabapentin/pregabalin) act on a different target — voltage-gated calcium channel subunits, dampening neuronal excitability — and do not carry the same augmentation signature, which is why guidance moved them to first line.

Why "secondary" matters mechanistically. Pregnancy (rising demands on iron, hormonal shifts), renal failure (impaired iron handling and uremic factors), and iron deficiency all converge on the same iron/dopamine axis from different directions — which is why removing the upstream cause (delivering the baby, repleting iron, dialysis optimisation) can resolve the syndrome rather than merely masking it. Culprit drugs work the other way: serotonergic antidepressants and dopamine-blocking agents perturb the same monoaminergic balance, so stopping or substituting them (a clinician decision) can lift symptoms at the source.

Why not every leg sensation qualifies. The criteria are mechanistically specific. Relief by movement and evening predominance are the discriminators: leg cramps are not relieved by movement (they are relieved by stretching the cramped muscle and have a different time course), neuropathy is typically constant rather than rest-triggered and movement-relieved, and akathisia is a generalised inner restlessness usually tied to dopamine-blocking drugs rather than a leg-localised, circadian urge. The criteria encode the mechanism.

Risks And Contraindications

• Iron is NOT universally safe. Do not blanket-recommend iron without a ferritin / transferrin-saturation check — over-supplementation risks overload (relevant in hemochromatosis carriers, repeated transfusion, and where inflammation elevates ferritin and masks true deficiency). IV iron carries a small hypersensitivity risk and belongs to clinicians. Dosing specifics are deferred to iron_supplementation_repletion_and_overload.
• Don't sell iron as a guaranteed fix. "Check your iron first" must not become "iron always works." It primarily helps when ferritin is low; normal-ferritin RLS often still needs other management.
• Alpha-2-delta ligands are not the "natural" answer. Gabapentin and pregabalin cause sedation, dizziness, peripheral edema, weight gain, and have misuse/dependence potential. Presenting them as benign is its own error.
• Augmentation incidence is a range, not a number. Quote it as roughly 7–10%/year new, ~20–30% cumulative — not a single false-precise figure.
• Never advise unilateral cessation of antidepressants or other prescribed drugs. Frame trigger-drug review as a clinician conversation; abrupt SSRI/SNRI discontinuation is harmful.
• Pregnancy and ESRD need specialist management. Iron and most RLS drugs carry pregnancy constraints; renal RLS needs renal/specialist input. Do not generalise the standard adult algorithm into these populations.
• Don't over-diagnose. The five criteria exist to exclude mimics. Treating cramps, neuropathy, or akathisia as RLS sends the workup down the wrong path.

Controversy

Nature: a both-ways tension between a real neurological disorder that is under-treated (where iron repletion is genuinely effective and badly under-used) and an over-medicalised / over-supplemented market (where dopamine agonists were over-prescribed and magnesium is over-sold). Error sits at both poles: dismissing RLS as anxiety, and reaching reflexively for a drug or a supplement before checking the cheap, causal lever.

Position A — "RLS is a real brain-iron disorder; check ferritin, replete iron, and avoid dopamine agonists long-term." The modern, guideline-aligned take.
• Best evidence: strong. Consistent diagnostic criteria, ~54–70% heritability with replicated risk genes (MEIS1, BTBD9), neuropathology showing low brain iron, an IRLSSG iron-treatment consensus with a ~75 µg/L ferritin target, and a 2024 AASM guideline that flipped first-line away from dopamine agonists because of augmentation.
• Where it must stay careful: iron is not unconditionally safe, IV iron is the most industry-aligned recommendation, and "check iron first" does not mean iron always works.

Position B — "Many cases are secondary or mimics, and the natural-cure market oversells supplements." The skeptical, de-prescribing take.
• Best evidence: correct on the specifics. A large fraction of cases are secondary (pregnancy, ESRD, iron deficiency, culprit drugs) and fixable by removing a trigger; magnesium has only one underpowered negative RCT plus case reports; and the five criteria exist to exclude cramps, neuropathy, and akathisia.
• Where it's wrong: if stretched into "it's not a real disorder" or "just supplement and relax," it ignores the genetics and neuropathology that make RLS unambiguously biological.

The funding/bias dimension — cui bono, both ways. Dopamine-agonist makers benefited from a first-line position won on 12-week trials too short to surface augmentation; the 2024 guideline flip and the augmentation literature run against that commercial interest, which raises their credibility. The supplement industry over-promotes magnesium far beyond its one-underpowered-RCT base; the systematic review debunking it has no commercial sponsor. IV-iron manufacturers do benefit from the ferric-carboxymaltose recommendation (and a key IRLSSG author has IV-iron research ties) — so the "IV iron as first-line" line is the one place industry interest aligns with the recommendation; the oral-iron-first, ferritin-threshold framing and the independent brain-iron neuropathology keep the core iron lever well-grounded.

Realised Position: RLS is real and mechanistically understood, so it deserves a workup, not dismissal — and the single most under-used lever is checking ferritin and repleting iron toward roughly 75–100 µg/L when it is low. Before adding any chronic drug, screen for a removable trigger (a sedating antihistamine, an SSRI/SNRI, alcohol) and treat secondary causes. If medication is needed, the modern evidence base favours alpha-2-delta ligands over dopamine agonists, because the agonists buy short-term relief at the cost of long-term augmentation. Magnesium is low-risk to try but should be sold as "thin evidence, maybe," not as a cure. Notice the pattern: the patient-favourable reading — check iron, remove triggers, avoid agonists long-term, don't oversell magnesium — is also the one least driven by industry money.

Cross-Pillar Connections

RLS is primarily a sleep disorder, but its levers reach into diet (iron status), mental (the dopamine axis and antidepressant triggers), and pharmacology.
• Diet / Supplements (iron_supplementation_repletion_and_overload): owns iron dosing, oral-versus-IV choice, and overload guardrails. This entry establishes that iron is the lever and roughly which ferritin target, then defers the how-to.
• Sleep / Supplements (magnesium_supplementation_sleep): owns the general magnesium-for-sleep evidence. This entry flags only that magnesium-for-RLS specifically is thin.
• Sleep (hypnotic_medications_overview): owns sedative-hypnotic pharmacology; RLS drugs are a separate class but patients often arrive on or asking about sleeping pills.
• Sleep (sleep_continuity): RLS is a major cause of fragmented sleep; the continuity entry holds the broader fragmentation picture this disorder feeds into.
• Mental (dopamine_motivation_baseline): the dopaminergic axis that underlies both RLS pathophysiology and the augmentation mechanism; also relevant to why dopamine-blocking and serotonergic drugs act as triggers.

What would change our mind

Falsifiability: explicit upgrade/downgrade criteria from source

• A large, well-powered RCT showing magnesium (or magnesium+B6) meaningfully reduces IRLS scores versus placebo would move magnesium off the "thin evidence" shelf toward Emerging.
• Long-term (multi-year) head-to-head data showing modern dopamine agonists with low augmentation rates — or showing alpha-2-delta ligands carry comparable long-term liabilities — would soften the first-line flip.
• Evidence that repleting ferritin to ~75–100 µg/L does NOT outperform placebo in low-ferritin RLS (current support is partly consensus/open-label rather than uniformly double-blind) would weaken the headline "check iron first" lever.
• A robust IV-iron RCT failing to replicate ferric-carboxymaltose benefit would specifically undercut the most industry-aligned recommendation.
• What would NOT move us: the existence of a biological substrate (convergent genetics + neuropathology), the diagnostic criteria, or the reality of augmentation. The convergence of guidelines, genetics, and neuropathology keeps this firmly at the Strong Evidence level.

Industry bias note

Structural incentives the evidence base may reflect

Cui bono cuts cleanly here, and mostly reinforces the entry's thesis.
• The dopamine-agonist makers: benefited from a first-line position won on ~12-week pivotal trials that were too short to surface augmentation. The 2024 AASM guideline flip and the augmentation literature run against that commercial interest — so disclosure of this risk is credibility-strengthening (cui bono cuts toward the patient, not industry).
• The supplement industry: over-promotes magnesium (and to a lesser extent vitamins) for RLS far beyond the one-underpowered-RCT base. The systematic review that debunks it has no commercial sponsor, so the skeptical position here is the financially disinterested one.
• The IV-iron manufacturers: do benefit from the ferric-carboxymaltose recommendation, and a key IRLSSG author (an IV-iron researcher) has industry ties. This is the one place where industry interest aligns with the recommendation — so treat "IV iron as first-line" as the most commercially-motivated line. The oral-iron-first, ferritin-threshold framing and the independent brain-iron neuropathology keep the core iron lever well-grounded.
• The clean signal: the patient-favourable reading — check iron, remove triggers, avoid dopamine agonists long-term, don't oversell magnesium — is also the one least driven by industry money. That is the tell that it tracks truth rather than a SKU.

Restless Legs Syndrome: Check Your Iron Before You Reach for a Drug